Review of the safety and efficacy of ustekinumab
| Autor: | Ellen Scherl, Sheila Kumar, Ryan Warren |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Crohn's disease
business.industry Multiple sclerosis Gastroenterology Interleukin Reviews Disease medicine.disease Infliximab law.invention Randomized controlled trial law Psoriasis Immunology Ustekinumab medicine lcsh:Diseases of the digestive system. Gastroenterology lcsh:RC799-869 business medicine.drug |
| Zdroj: | Therapeutic Advances in Gastroenterology, Vol 3 (2010) |
| ISSN: | 1756-2848 |
| Popis: | Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn’s disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn’s disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|